Lipid Insights

What does your patient's lipid panel actually tell you and what is it missing? In this special National Lipid Day episode of Lipid Insights, host Peter H. Jones, MD, MNLA, sits down with Thomas Dayspring, MD, FACP, MNLA — widely known as "The Lipid Doctor" — for a conversation that challenges some of medicine's most entrenched assumptions about lipid risk assessment. From the clinical superiority of ApoB over LDL-C and the underrecognized atherogenic burden of Lipoprotein(a), to why HDL-C should no longer be treated as a therapeutic target, Dr. Dayspring delivers evidence-based truths that have direct implications for how clinicians assess and manage cardiovascular risk. If you order lipid panels, counsel patients on cholesterol, or manage ASCVD risk in any capacity — this episode is essential listening.

Follow @drlipid on X (Twitter) and LinkedIn.
https://x.com/Drlipid
https://www.linkedin.com/in/thomas-dayspring-md-facp-fnla-3aaa876/

In this episode of Lipid Insights, host Peter H. Jones, MD, MNLA sits down with Nivedita Patni, MD, of the Department of Pediatrics at UT Southwestern Medical Center in Dallas, TX, to explore the complex landscape of pediatric dyslipidemia. Dr. Patni walks through the critical importance of tailoring management to etiology, the long-term cardiovascular and metabolic risks that hang in the balance, and why early identification is everything.

Drawing on case studies and evidence-based management strategies, Dr. Patni shares practical implementation guidelines for clinicians navigating these challenging diagnoses — including the challenges that make rare lipid disorders in children so easy to overlook and so difficult to treat. She also highlights the essential role of multidisciplinary care, bringing together endocrinology, dietetics, and family support to deliver truly individualized treatment.

Whether you're seeing these patients regularly or encountering them for the first time, this episode will sharpen your clinical lens and equip you with actionable strategies to make a difference early.

Childhood obesity is one of the most pressing public health challenges of our time — and its long-term cardiovascular and metabolic consequences make it essential territory for lipidologists and clinicians alike.

In this episode of Lipid Insights, host Peter H. Jones, MD, MNLA sits down with Casey Berman, MD to explore the full picture: how childhood obesity is defined, why its prevalence continues to rise, and the behavioral, societal, and genetic factors fueling the epidemic. They also dive into associated comorbidities and the latest prevention and management strategies — from lifestyle modifications and pharmacotherapy to the evolving role of bariatric and metabolic surgery.

A must-listen for any clinician looking to better support their youngest patients.

Join host Dr. Peter H. Jones for a special episode of Lipid Insights discussing the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Dr. Jones is joined by guideline author and NLA Past President Dr. Joseph Saseen and NLA President-Elect Dr. Dinesh Kalra to break down what clinicians need to know.
From the restoration of LDL-C treatment goals and major conceptual shifts from the 2018 guideline, to primordial and primary prevention, risk assessment, special populations, and real-world implementation challenges, this episode covers it all. The panel also explores the guideline's expanded scope beyond LDL-C to include triglycerides, Lp(a), ApoB, and more.
This is a must-listen episode for anyone involved in dyslipidemia management.
Read the Guidelines here: https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016

In this episode of Lipid Insights, we explore the NLA's recent expert meta-analysis, "Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials."
 
Lead author Dinesh K. Kalra, MD, MBA and key author Kevin C. Maki, PhD, CLS, MNLA join host Alan S. Brown, MD, MHA, MNLA to examine the relationship between LDL-C reduction and major adverse cardiovascular events in primary prevention trials. Together, they break down the findings, clinical implications, and why early LDL-C lowering remains central to preventing first cardiovascular events.

Read the meta-analysis: https://www.lipidjournal.com/article/S1933-2874(26)00039-5/fulltext